Navistar

Device Medical Device Business Services, Inc.
Total Payments
$760,234
Transactions
543
Doctors
110
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2024 $9,293 9 6
2023 $36,799 17 14
2022 $18,315 46 7
2021 $4,169 9 2
2020 $2,144 7 2
2019 $259,979 25 12
2018 $121,626 172 37
2017 $307,910 258 61

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $650,241 89 85.5%
Travel and Lodging $83,433 90 11.0%
Food and Beverage $10,309 361 1.4%
Consulting Fee $9,268 2 1.2%
Gift $6,984 1 0.9%

Payments by Type

Research
$650,241
89 transactions
General
$109,994
454 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Electrogram-Guided Myocardial Advanced Phenotyping (The eMAP Trial) Medical Device Business Services, Inc. $329,410 0
NAVISTAR THERMOCOOL Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation-Post Approval Registry, PMA - AF Registry Medical Device Business Services, Inc. $232,096 0
Cardiac positron emission tomography for detection of cardiac sympathetic dysinnervation to guide ablation of ventricular tachycardia (PET VT Study) Biosense Webster, Inc. $35,864 0
NAVISTAR THERMOCOOL Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation - Post Approval Registry Medical Device Business Services, Inc. $27,090 0
Navistar Thermocool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation-Post Approval Registry, PMA - AF Registry Medical Device Business Services, Inc. $13,318 0
Standard Ablation v. MRI-guided Ablation in the Treatment of Ventricular Tachycardia Medical Device Business Services, Inc. $7,000 0
NAVISTAR THERMOCOOL Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation Post Approval Registry Medical Device Business Services, Inc. $3,400 0
NAVISTAR THERMOCOOL Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation Post Approval Registry Medical Device Business Services, Inc. $2,063 0

Top Doctors Receiving Payments for Navistar

Doctor Specialty Location Total Records
Unknown Philadelphia, PA $657,225 90
, M.D Clinical Cardiac Electrophysiology Boston, MA $16,141 7
, M.D Student in an Organized Health Care Education/Training Program Detroit, MI $16,019 6
, M.D Cardiovascular Disease Murray, UT $15,481 26
, MD, PHD Cardiovascular Disease Bronx, NY $9,377 7
, MD Internal Medicine Boston, MA $9,029 2
, M.D Internal Medicine Salt Lake City, UT $7,699 3
, MD Cardiovascular Disease Austin, TX $7,534 17
, M.D Cardiovascular Disease Santa Monica, CA $4,622 21
, M.D Cardiovascular Disease Lexington, KY $2,670 8
, M.D Cardiovascular Disease Tupelo, MS $1,572 3
, M.D Cardiovascular Disease Austin, TX $1,188 5
, M.D Clinical Cardiac Electrophysiology Parlin, NJ $710.55 26
, MD Internal Medicine Elk Grove Village, IL $686.40 2
, M.D Internal Medicine Chicago, IL $507.45 1
, M.D Internal Medicine San Francisco, CA $495.25 2
, M.D Cardiovascular Disease Morristown, NJ $489.75 44
, MD Clinical Cardiac Electrophysiology Morristown, NJ $470.24 38
, MD Clinical Cardiac Electrophysiology Los Angeles, CA $421.00 2
, MD Clinical Cardiac Electrophysiology Morristown, NJ $413.16 33
, M.D Clinical Cardiac Electrophysiology Morristown, NJ $406.94 33
, MD Clinical Cardiac Electrophysiology Cleveland, OH $389.15 3
, MD Clinical Cardiac Electrophysiology Morristown, NJ $372.06 47
, M.D Clinical Cardiac Electrophysiology Murray, UT $364.03 2
, MD Cardiovascular Disease Oakland, CA $308.60 1

About Navistar

Navistar is a device associated with $760,234 in payments to 110 healthcare providers, recorded across 543 transactions in the CMS Open Payments database. The primary manufacturer is Medical Device Business Services, Inc..

Payment data is available from 2017 to 2024. In 2024, $9,293 was paid across 9 transactions to 6 doctors.

The most common payment nature for Navistar is "Unspecified" ($650,241, 85.5% of total).

Navistar is associated with 8 research studies, including "Electrogram-Guided Myocardial Advanced Phenotyping (The eMAP Trial)" ($329,410).